Quantcast

Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States

December 2, 2008

MALVERN, Pa., Dec. 2 /PRNewswire/ — Arlington Medical Resources (AMR), a
provider of premier market intelligence for the pharmaceutical and diagnostic
imaging industries, finds that Ortho-McNeil-Janssen Pharmaceuticals’ Levaquin
is the preferred quinolone antibiotic among more than half of all general
medical-surgical hospitals in the United States. Quinolone antibiotics are
used to treat lung, sinus, skin and urinary tract infections caused by
numerous bacterial pathogens.

“Based on our October 2008 audit, intravenous Levaquin was stocked in more
hospitals than both Bayer’s intravenous Cipro and generic intravenous
ciprofloxacin combined,” stated Matthew W. Mahr, Pharm.D., M.B.A., analyst at
AMR.

The newly released edition of the Quinolone Monthly Monitor (U.S.) also
finds that over 70 percent of hospitals reported having a closed hospital
formulary for antibiotics. Large hospitals were found to be most likely to
have a closed formulary for antibiotics. These closed formularies create
restrictions on what can be prescribed in the hospital making it more
difficult for a prescriber to use that medication.

Why Pharmaceutical Companies Need this Information

The Quinolone Monthly Monitor (U.S.) enables pharmaceutical companies to
monitor formulary, stocking and restriction status of selected quinolone
antibiotics. This study also gives information about the Pharmacy and
Therapeutics Committee’s actions for quinolones, which drive formulary and
restriction status for these products.

About The Quinolone Monthly Monitor (U.S.)

The Quinolone Monthly Monitor (U.S.) is the industry’s most comprehensive
market research study of the formulary status of quinolone antibiotics. This
study has been conducted monthly since June 1992 by collecting data from 300
pharmacy directors from a group of demographically representative acute care
hospitals within the country.

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the
pharmaceutical and diagnostic imaging industries. Research includes clinical
inpatient databases that directly link anti-infective drug with
indication/procedure, formulary and stocking status tracking studies, drug
purchasing audits and diagnostic imaging procedure volume/contrast media usage
audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

    Natalia Morales             Elizabeth Marshall
    Decision Resources          Decision Resources, Inc.
    781-296-2691                781-296-2563
    nmorales@dresources.com     emarshall@dresources.com

SOURCE Arlington Medical Resources


Source: newswire



comments powered by Disqus